Stockreport

Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma

Synlogic, Inc.  (SYBX) 
Last synlogic, inc. earnings: 3/12 04:19 pm Check Earnings Report
PDF CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to [Read more]